Advertisement

Pharmaceutisch Weekblad

, Volume 9, Supplement 1, pp S48–S52 | Cite as

Long-term oral ciprofloxacin for infection prophylaxis in allogeneic bone marrow transplantation

  • T. de Witte
  • I. Novakova
  • J. Branolte
  • H. Muytjens
  • B. de Pauw
Article

Abstract

The efficacy of oral ciprofloxacin to prevent bacterial infections during the first three months after allogeneic bone marrow transplantation (BMT) was assessed prospectively. Twenty-three recipients of lymphocyte depleted marrow grafts received ciprofloxacin orally, 500 mg twice daily for 90 days after BMT. Nine patients had no infections during ciprofloxacin prophylaxis; in the remaining 14 patients 19 febrile episodes occurred. No infections could be attributed to Gram-negative rods nor to fungal micro-organisms on the basis of the micro-organisms isolated. One infection, a pneumonia due toBacteroides melaninogenicus, proved to be fatal. Allergic skin reactions were observed in three patients, but neither hematological nor nephrological side-effects could be substantiated in patients who were treated concomitantly with cyclosporine. Prolonged administration of ciprofloxacin turned out to be safe and effective in preventing serious aerobic bacterial infections during the first three months after BMT.

Key words

Ciprofloxacin Prophylaxis Transplantation, bone marrow 

References

  1. 1.
    Winston DJ, Ho G, Champlin RE, and Gale RP. Infectious complications of bone marrow transplantation. Exp Hematol 1984;12:205–15.PubMedGoogle Scholar
  2. 2.
    Van der Waay D. Colonization resistance of the digestive tract: clinical consequences and implications. J Antimicrob Chemother 1982;10:263–70.PubMedGoogle Scholar
  3. 3.
    Thompson JF, Chalmers DHK, Hunnisett AGW, Wood RFM, Morris PJ. Nephrotoxicity of trimethoprim and cotrimoxazole in renal allograft recipients treated with cyclosporin. Transplantation 1983;36:204–7.PubMedGoogle Scholar
  4. 4.
    Brumfitt W, Franklin I, Grady D, Hamilton-Miller JMT, and Iliffe A. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob Agents Chemother 1984;26:757–61.PubMedGoogle Scholar
  5. 5.
    Muytjens HL, Van der Ros-van de Repe J, Van Veldhuizen G. Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and naladixic acid. Antimicrob Agents Chemother 1983;24:302–4.PubMedGoogle Scholar
  6. 6.
    De Witte T, Raymakers R, Plas A, Koekman E, Wessels J, and Haanen C. Bone marrow repopulation capacity after allegeneic bone marrow transplantation of lymphocyte depleted bone marrow using counterflow centrifugation. Transplantation 1984;37:151–5.PubMedGoogle Scholar
  7. 7.
    Cohen J, Donelly JP, Worsley AM, et al. Septicemia caused by viridans streptococci in neutropenic patients with leukemia. Lancet 1983;II:1452–4.Google Scholar
  8. 8.
    Winston DJ, Ho WG, Nakao SL, Gale RP, and Champlin RE. Norfloxacin versus Vancomycin/Polymyxin for prevention of infections in granulocytopenic patients. Am J Med 1986;80:884–90.PubMedGoogle Scholar

Copyright information

© Bohn, Scheltema & Holkema 1987

Authors and Affiliations

  • T. de Witte
    • 1
  • I. Novakova
    • 1
  • J. Branolte
    • 2
  • H. Muytjens
    • 3
  • B. de Pauw
    • 1
  1. 1.Division of Haematology Department of Internal MedicineUniversity HospitalNijmegenThe Netherlands
  2. 2.Medical DepartmentBayer Nederland B.V.MijdrechtThe Netherlands
  3. 3.Department of Medical MicrobiologyUniversity HospitalNijmegenThe Netherlands

Personalised recommendations